Jilin Jian Yisheng Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Jilin Jian Yisheng Pharmaceutical Co Ltd cash flow-to-debt ratio. Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥8.20 Million could theoretically repay 0% of its total liabilities (CN¥658.86 Million) in one year. Check total reinvestment intensity of Jilin Jian Yisheng Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jilin Jian Yisheng Pharmaceutical Co Ltd (2006–2025)
Cash flow-to-debt ratio of Jilin Jian Yisheng Pharmaceutical Co Ltd from 2006 to 2025. Historical debt coverage capacity for Jilin Jian Yisheng Pharmaceutical Co Ltd across 20 annual periods. Check earnings quality score of Jilin Jian Yisheng Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Jilin Jian Yisheng Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2006–2025)
Jilin Jian Yisheng Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2006 to 2025. Year-by-year debt coverage analysis for Jilin Jian Yisheng Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see how efficiently does Jilin Jian Yisheng Pharmaceutical Co Ltd generate cash.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | CN¥98.74 Million | CN¥630.35 Million | ▲ +69.3% |
| 2024 | 0.09x | CN¥58.94 Million | CN¥637.22 Million | ▼ -68.4% |
| 2023 | 0.29x | CN¥209.13 Million | CN¥714.30 Million | ▲ +44.0% |
| 2022 | 0.20x | CN¥145.86 Million | CN¥717.18 Million | ▼ -37.0% |
| 2021 | 0.32x | CN¥215.10 Million | CN¥666.08 Million | ▲ +5.3% |
| 2020 | 0.31x | CN¥203.51 Million | CN¥663.86 Million | ▼ -36.2% |
| 2019 | 0.48x | CN¥210.87 Million | CN¥438.66 Million | ▲ +68.8% |
| 2018 | 0.28x | CN¥167.32 Million | CN¥587.49 Million | ▼ -20.4% |
| 2017 | 0.36x | CN¥270.65 Million | CN¥756.40 Million | ▲ +1875.9% |
| 2016 | -0.02x | CN¥-17.52 Million | CN¥869.67 Million | ▲ +94.5% |
| 2015 | -0.36x | CN¥-324.29 Million | CN¥888.65 Million | ▲ +54.4% |
| 2014 | -0.80x | CN¥-592.06 Million | CN¥739.24 Million | ▲ +9.1% |
| 2013 | -0.88x | CN¥-188.45 Million | CN¥213.79 Million | ▼ -181.2% |
| 2012 | 1.09x | CN¥79.08 Million | CN¥72.81 Million | ▲ +162.5% |
| 2011 | -1.74x | CN¥-112.12 Million | CN¥64.52 Million | ▼ -633.3% |
| 2010 | 0.33x | CN¥50.73 Million | CN¥155.66 Million | ▼ -61.8% |
| 2009 | 0.85x | CN¥125.25 Million | CN¥146.67 Million | ▲ +430.9% |
| 2008 | 0.16x | CN¥20.50 Million | CN¥127.43 Million | ▼ -73.5% |
| 2007 | 0.61x | CN¥82.66 Million | CN¥136.08 Million | ▲ +135.9% |
| 2006 | 0.26x | CN¥25.58 Million | CN¥99.35 Million | — |